文献速递脑血管病认知障碍与痴呆

ARTEMIDA试验:Actovegin治疗卒中后认知障碍的随机对照研究

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
PubMed 文献 · Stroke · 2017-01-01

这项为期12个月的多中心双盲安慰剂对照试验纳入年龄≥60岁、简易智力状态检查(MoCA)≤25分的急性幕上缺血性卒中患者,比较Actovegin与安慰剂的认知疗效。主要终点为6个月时阿尔茨海默病评估量表认知扩展版(ADAS-cog)较基线的变化,Actovegin组为-6.8,安慰剂组为-4.6,估计治疗差异为-2.3(95%CI -3.9至-0.7;P=0.005)。结论认为Actovegin对卒中后认知障碍患者有认知获益,安全性经验与已知特征一致,但需进一步研究确认。

要点

  • Actovegin组6个月ADAS-cog较基线变化-6.8,安慰剂组-4.6,治疗差异-2.3(P=0.005)。
  • 研究纳入≥60岁、MoCA≤25分的急性幕上缺血性卒中患者。
  • 复发缺血性卒中为最常见严重不良事件,Actovegin组数值上高于安慰剂但无统计学意义。

核心结论

  • Actovegin对卒中后认知障碍患者的认知结局具有有益效应。
  • 安全性经验与Actovegin已知的安全性和耐受性特征一致。
  • 作者认为这些结果需要在更多稳健设计的研究中确认。

研究设计与样本

  • 12个月、平行组、随机、多中心、双盲、安慰剂对照研究。
  • 纳入年龄≥60岁、MoCA评分≤25分的急性幕上缺血性卒中患者,卒中后1周内按1:1随机分组。
  • Actovegin组(小牛血去蛋白提取物,2000 mg/d静脉输注≤20次后改为1200 mg/d口服)或安慰剂治疗6个月,之后按标准临床实践随访6个月。
  • 主要终点为6个月时ADAS-cog扩展版较基线的变化。

主要发现

  • 6个月时ADAS-cog扩展版较基线最小二乘均值变化:Actovegin组-6.8,安慰剂组-4.6。
  • 估计治疗差异为-2.3(95%CI -3.9至-0.7;P=0.005)。
  • 复发缺血性卒中为最常报告的严重不良事件,Actovegin组数值上高于安慰剂组但无统计学显著性。

局限性

  • 作者指出结果需要在更多稳健设计的研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Poststroke cognitive impairment is a debilitating consequence of stroke. The aim of this study was to assess whether Actovegin confers cognitive benefit in patients who have had an ischemic stroke. METHODS: This was a 12-month, parallel-group, randomized, multicenter, double-blind, placebo-controlled study. Eligible patients were ≥60 years of age with a Montreal Cognitive Assessment test score of ≤25 points. Patients were randomized into 2 groups within 1 week of acute supratentorial ischemic stroke in a 1:1 ratio: Actovegin (a deproteinized hemoderivative of calf blood, 2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally) or placebo for 6 months. Patients were treated in accordance with standard clinical practice for a further 6 months. The primary end point was the change from baseline in Alzheimer's Disease Assessment Scale, cognitive subscale, extended version at 6 months. RESULTS: Two-hundred forty-eight patients were randomized to Actovegin and 255 patients to placebo. At month 6, the least squares mean change from baseline in Alzheimer's Disease Assessment Scale, cognitive subscale, extended version was -6.8 for Actovegin and -4.6 for placebo; the estimated treatment difference was -2.3 (95% confidence interval, -3.9, -0.7; P=0.005). Recurrent ischemic stroke was the most frequently reported serious adverse event, with a nonsignificantly higher number for Actovegin versus placebo. CONCLUSIONS: Actovegin had a beneficial effect on cognitive outcomes in patients with poststroke cognitive impairment. The safety experience was consistent with the known safety and tolerability profile of the drug. These results warrant confirmation in additional robustly designed studies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01582854.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017. PMID: 28432265. doi:10.1161/STROKEAHA.116.014321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。